Download PDF
Horm Metab Res 2001; 33(9): 536-539
DOI: 10.1055/s-2001-17214
Original Clinical

© Georg Thieme Verlag Stuttgart · New York

Growth Hormone and Prolactin Secretion after Metoclopramide Administration (DA2 Receptor Blockade) in Fertile Women[*]

J. S. Cunha-Filho 1 , J. L. Gross 2 , D. Vettori 1 , E. C. Dias 1 , E. P. Passos 1
  • 1 Obstetrics and Gynecology Department, Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Brazil
  • 2 Endocrinology Division, Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Brazil
Further Information

Publication History

Publication Date:
17 September 2001 (online)

Also available at
    Permissions and Reprints

In this report, we will describe the results of a cross-sectional study to assess PRL and GH secretion during the early follicular phase in 22 fertile patients after metoclopramide administration in order to achieve a dopaminergic DA2 receptor blockade. Blood samples were collected at - 15, 0, 15, 30, 45 and 60 minutes. PRL, GH, estradiol, IGF-I, TSH, glucose, and insulin were measured in the samples taken at - 15 and 0 minutes. The existence of a correlation between GH and PRL secretion was investigated. All patients presented normal serum levels of estradiol, prolactin, insulin, fasting glucose and IGF-I. Serum GH levels were not changed after metoclopramide infusion (p = 0.302), but there was a significant alteration in serum PRL (p = 0.0001) with the highest levels after 30 (mean: 237.20 ng/ml ± 95.86) and 45 (mean: 211.80 ng/ml ± 83.24) minutes. Serum GH levels did not correlate with serum PRL levels after the dopaminergic DA2 blockade. We conclude that GH secretion was not modulated by a direct effect of type 2 dopamine receptor.

Key words:

GHRH - Somatostatin - GH Secretion - Dopamine DA2 Receptor - Metoclopramide Administration

1 This research was supported by grants from the Post-Graduate Program in Endocrinology, Universidade Federal do Rio Grande do Sul, and Grupo de Pesquisa e Pós-Graduação, Hospital de Clinicas de Porto Alegre, Brazil.

References

  • 1 Katz E, Ricciarelli E, Adashi E Y. The potential relevance of growth hormone to female reproductive physiology and pathophysiology.  Fertil Steril. 1993;  59 8-34
    PubMedGoogle Scholar
  • 2 Devesa J, Lima L, Tresguerres A F. Neuroendocrine control of growth hormone secretion in humans.  Trends Endocrinol Metab. 1992;  3 175-183
    PubMedGoogle Scholar
  • 3 Argente J, Pozo J, Chowen J A. The growth hormone axis: control and effects.  Norm Res. 1996;  45 9-11
    PubMedGoogle Scholar
  • 4 Multer E E, Folia M, Ghigo E, Belliti D, Arvat E, Andreoni  A, Torsello A, Locatelli V, Camanni F. Involvement of brain catecholamines and acetylcholine in growth hormone hypersecretory states. Pathophysiological, diagnostic and therapeutic implications.  Rugs. 1995;  50 805-37
    PubMedGoogle Scholar
  • 5 Müller-Spahn F, Modell S, Ackenheil M, Brachner A, Kutz G. Elevated response of growth hormone to graded doses of apomorphine in schizophrenic patients.  J Psychiatr Res. 1998;  32 265-271
    CrossrefPubMedGoogle Scholar
  • 6 Vance M L, Kaiser  D L, Frohman L A, Rivier J, Vale W W, Thomer M O. Role of dopamine in the regulation of Growth Hormone secretion: dopamine and bromocriptine augment growth hormone-τ releasing hormone stimulated GH secretion in normal man.  J Clin Endocrinol Metab. 1987;  64 1136-1141
    PubMedGoogle Scholar
  • 7 Arce V, Lima L, Lois N, Rodriguez A, Diaz M J, Tresguerres J A, Devesa J. Role of central dopaminergic pathways in the neural control of growth hormone secretion in normal men: studies with metoclopramide.  Neuroendocrinology. 1991;  53 143-149
    PubMedGoogle Scholar
  • 8 Masala A, Delitala G, Alagna S, Devilla L, Rovasio P P, Lotti G. Effect of dopaminergic blockade on the secretion of growth hormone and prolactin in man.  Metabolism. 1978;  27 921-926
    CrossrefPubMedGoogle Scholar
  • 9 Cohen H N, Hay I D, Thonson J A, Logue F, Ratcliffe W A, Beastall G H. Metoclopramide stimulation: a test of growth hormone reserve in adolescent males.  Clin Endocrinol. 1979;  11 89-93
    PubMedGoogle Scholar
  • 10 Chiodera P, Coiro V, Zanardi G, Volpi R, Valenti G, Butturini U. Effect of metoclopramide on serum GH levels in normal women.  Horm Metab Res. 1982;  14 103-104
    PubMedGoogle Scholar
  • 11 Jordan V, Dieguez C, Lafaffian I, Rodriguez-Arnao M D, Gomez-Pan A, Hall R, Scanlon M F. Influence of dopaminergic, adrenergic and cholinergic blockade and TRH administration on GH responses to CRF 1-29.  Clin Endocrinol. 1986;  29 291-298
    PubMedGoogle Scholar
  • 12 Volpi R, Coiro V, Salvi M, Pelosi G, Mancini P, Chiodera P. Effect of metoclopramide on serum growth hormone levels in cirrhotic men.  J Endocrinol Invest. 1983;  6 101-105
    PubMedGoogle Scholar
  • 13 Fang V S, Shian L R. A serotonergic mechanism of the prolactin stimulating action of metoclopramide.  Endocrinology. 1981;  108 1622-1627
    PubMedGoogle Scholar
  • 14 Andersen A N, Tabor A. PRL, TSH, GH and LH responses to metoclopramide and breast-feeding in normal and hyperprolactinemic women.  Acta Endocrinol. 1982;  100 177-183
    PubMedGoogle Scholar

1 This research was supported by grants from the Post-Graduate Program in Endocrinology, Universidade Federal do Rio Grande do Sul, and Grupo de Pesquisa e Pós-Graduação, Hospital de Clinicas de Porto Alegre, Brazil.

Dr. J. S. Cunha-Filho

Departamento de Ginecologia e Obstetricia
Hospital de Clinicas de Porto Alegre

Rua Ramiro Barcetos, 2350-11° andar
90035-003 Porto Alegre, RS
Brazil


Phone: + 55 (51) 3346-7155

Fax: + 55 (51) 3346-7155

Email: sabino@via-rs.net

      >